BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36036607)

  • 1. Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race.
    Zimmerman R; Bilen MA; Heath EI; Nandagopal L; Swami U; Kessel A; Jaeger E; Wesolowski S; Hernanadez EJ; Chipman J; Mack A; Ravindranathan D; Maughan BL; Nussenzveig R; Yandell M; Kohli M; Lilly MB; Sartor AO; Agarwal N; Barata PC
    Oncologist; 2022 Oct; 27(10):e815-e818. PubMed ID: 36036607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis.
    Sivakumar S; Lee JK; Moore JA; Hopkins J; Newberg JY; Madison R; Graf R; Schrock AB; Kobetz E; Vince R; Franco I; Seldon C; Frampton GM; Mills J; Venstrom J; Mahal BA
    Lancet Digit Health; 2023 Jun; 5(6):e380-e389. PubMed ID: 37236698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
    Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
    Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic landscape of advanced prostate cancer patients with
    Swami U; Zimmerman RM; Nussenzveig RH; Hernandez EJ; Jo Y; Sayegh N; Wesolowski S; Kiedrowski LA; Barata PC; Lemmon GH; Bilen MA; Heath EI; Nandagopal L; Babiker HM; Pal SK; Lilly M; Maughan BL; Haaland B; Yandell M; Sartor O; Agarwal N
    Front Oncol; 2022; 12():966534. PubMed ID: 36185208
    [No Abstract]   [Full Text] [Related]  

  • 5. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
    Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
    JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Genomic Alterations in Prostate Tumors Derived from African American Men.
    Liu W; Zheng SL; Na R; Wei L; Sun J; Gallagher J; Wei J; Resurreccion WK; Ernst S; Sfanos KS; Isaacs WB; Xu J
    Mol Cancer Res; 2020 Dec; 18(12):1815-1824. PubMed ID: 33115829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 8. Studying Copy Number Variations in Cell-Free DNA: The Example of AR in Prostate Cancer.
    Salvi S; Casadio V
    Methods Mol Biol; 2019; 1909():95-103. PubMed ID: 30580425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.
    Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Kageyama R; Wells DK; Chan JM; Friedlander T; Aggarwal R; Paris PL; Feng F; Carroll PR; Witte JS
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.
    Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Chu C; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Chan JM; Friedlander T; Wyatt AW; Aggarwal R; Paris PL; Carroll PR; Feng F; Witte JS
    Sci Rep; 2021 Mar; 11(1):5040. PubMed ID: 33658587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.
    Kubota Y; Hatakeyama S; Yoneyama T; Yoneyama MS; Hamano I; Konishi S; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
    World J Urol; 2021 Sep; 39(9):3265-3271. PubMed ID: 33675416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
    Ledet EM; Lilly MB; Sonpavde G; Lin E; Nussenzveig RH; Barata PC; Yandell M; Nagy RJ; Kiedrowski L; Agarwal N; Sartor O
    Oncologist; 2020 Apr; 25(4):327-333. PubMed ID: 32297439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
    Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
    Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using circulating cell-free DNA to monitor personalized cancer therapy.
    Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
    Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer.
    Xia Y; Huang CC; Dittmar R; Du M; Wang Y; Liu H; Shenoy N; Wang L; Kohli M
    Oncotarget; 2016 Jun; 7(24):35818-35831. PubMed ID: 27127882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.
    Gupta S; Hovelson DH; Kemeny G; Halabi S; Foo WC; Anand M; Somarelli JA; Tomlins SA; Antonarakis ES; Luo J; Dittamore RV; George DJ; Rothwell C; Nanus DM; Armstrong AJ; Gregory SG
    Genes Chromosomes Cancer; 2020 Apr; 59(4):225-239. PubMed ID: 31705765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference.
    Jensen K; Konnick EQ; Schweizer MT; Sokolova AO; Grivas P; Cheng HH; Klemfuss NM; Beightol M; Yu EY; Nelson PS; Montgomery B; Pritchard CC
    JAMA Oncol; 2021 Jan; 7(1):107-110. PubMed ID: 33151258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen-Mediated Activation of H875Y Androgen Receptor Mutation in a Prostate Cancer Patient.
    Vasudevamurthy AK; Ledet E; Garvey C; Lewis BE; Sartor O
    Clin Genitourin Cancer; 2017 Feb; 15(1):e111-e113. PubMed ID: 27527401
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.
    Fettke H; Kwan EM; Bukczynska P; Ng N; Nguyen-Dumont T; Southey MC; Davis ID; Mant A; Parente P; Pezaro C; Hauser C; Azad AA
    Eur Urol Focus; 2021 Nov; 7(6):1287-1291. PubMed ID: 32739405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients.
    Lieb V; Abdulrahman A; Weigelt K; Hauch S; Gombert M; Guzman J; Bellut L; Goebell PJ; Stöhr R; Hartmann A; Wullich B; Taubert H; Wach S
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.